Arizona State Retirement System Cuts Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Arizona State Retirement System lowered its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 1.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 9,122 shares of the company’s stock after selling 147 shares during the quarter. Arizona State Retirement System’s holdings in TransMedics Group were worth $720,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in TMDX. FMR LLC grew its stake in shares of TransMedics Group by 42.5% during the 3rd quarter. FMR LLC now owns 4,714,870 shares of the company’s stock worth $258,139,000 after purchasing an additional 1,407,171 shares during the period. Eventide Asset Management LLC grew its position in TransMedics Group by 1,271.7% during the third quarter. Eventide Asset Management LLC now owns 925,356 shares of the company’s stock worth $50,663,000 after buying an additional 857,895 shares during the period. Summit Partners Public Asset Management LLC increased its holdings in TransMedics Group by 71.9% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 957,282 shares of the company’s stock valued at $59,083,000 after buying an additional 400,255 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in TransMedics Group by 91.4% in the third quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock valued at $41,615,000 after buying an additional 363,012 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of TransMedics Group by 271.2% during the 3rd quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock valued at $26,661,000 after acquiring an additional 355,755 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,000 shares of the stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at approximately $7,044,932.83. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Edward M. Basile sold 7,157 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total value of $618,221.66. Following the completion of the sale, the director now directly owns 8,350 shares in the company, valued at $721,273. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 12,000 shares of the business’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the sale, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at $7,044,932.83. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 119,408 shares of company stock valued at $10,182,881. Company insiders own 6.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. JPMorgan Chase & Co. raised their price objective on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Piper Sandler initiated coverage on TransMedics Group in a research report on Thursday, March 28th. They issued an “overweight” rating and a $95.00 price target for the company. Oppenheimer lifted their price target on TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. Finally, Morgan Stanley increased their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus price target of $102.00.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $87.24 on Friday. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $99.63. The business has a fifty day moving average of $82.97 and a 200-day moving average of $72.98. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of -113.30 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.22. The firm had revenue of $81.20 million during the quarter, compared to the consensus estimate of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The firm’s revenue for the quarter was up 158.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.21) EPS. As a group, analysts predict that TransMedics Group, Inc. will post -0.14 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.